Ahmadvand Simin, Norouzi Lotf-Ali, Mohammadi Yousef, Safaei Akbar, Khademi Bijan, Motiee-Langroudi Maziar, Ghaderi Abbas
Department of Biochemistry, Microbiology, and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Otolaryngology Research Centre, Department of Otorhinolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran.
BMC Immunol. 2024 Jan 16;25(1):7. doi: 10.1186/s12865-024-00597-0.
Biomarkers that can predict outcome will improve the efficacy of treatment for HNSCC patients. In this regard, we retrospectively evaluated the prognostic effect of PD1, PD-L1, and CD45RO in tongue and larynx squamous cell carcinomas.
FFPE tissue blocks of 63 larynx and 40 tongue squamous cell carcinoma samples were selected, cut into 3 µm sections, and immunohistochemically stained for PD1, PD-L1, and CD45RO. The slides were evaluated by an expert pathologist, and results were analysed using Chi-square, univariate, and multivariable Cox regression methods.
TC-PD-L1 expression (P = 0.001) and its expression intensity (P = 0.002) were significantly correlated with a higher percentage of PD-1 + tumor infiltrating lymphocytes. In univariate survival analysis, TC-PD-L1 and its expression intensity had a significant impact on both DFS (HR: 0.203; P = 0.003 and HR: 0.320; P = 0.005) and OS (HR: 0.147; P = 0.002 and HR: 0.322; P = 0.005). Based on the multivariate analysis, PD1 (DFS: HR: 3.202; P = 0.011, OS: HR: 2.671; P = 0.027) and TC-PD-L1 (DFS: HR: 0.174; P = 0.006, OS: HR: 0.189; P = 0.009) were found to be independent prognostic markers. In the second part, scoring systems were defined based on the expression status of PD1 and PD-L1. Patients with higher scores were expected to have longer DFS and OS. In multivariate analysis, the PD1/TC-PD-L1 (DFS: P = 0.001, OS: P = 0.003) scoring systems showed superior prognostic effects. Interestingly, at the highest levels of this score, none of the patients experienced recurrence or cancer-caused death.
Collectively, this study suggests negative prognostic behaviour for TC-PD-L1 protein and introduces the PD-1/TC-PD-L1 scoring system as a strong prognostic marker in OS and DFS prediction of tongue and larynx HNSCC patients.
能够预测预后的生物标志物将提高头颈部鳞状细胞癌(HNSCC)患者的治疗效果。在这方面,我们回顾性评估了PD1、PD-L1和CD45RO在舌癌和喉癌鳞状细胞癌中的预后作用。
选取63例喉鳞状细胞癌和40例舌鳞状细胞癌样本的福尔马林固定石蜡包埋(FFPE)组织块,切成3μm切片,进行PD1、PD-L1和CD45RO的免疫组织化学染色。由专业病理学家对切片进行评估,并采用卡方检验、单因素和多因素Cox回归方法分析结果。
肿瘤中心(TC)-PD-L1表达(P = 0.001)及其表达强度(P = 0.002)与较高比例的PD-1 +肿瘤浸润淋巴细胞显著相关。在单因素生存分析中,TC-PD-L1及其表达强度对无病生存期(DFS,风险比[HR]:0.203;P = 0.003和HR:0.320;P = 0.005)和总生存期(OS,HR:0.147;P = 0.002和HR:0.322;P = 0.005)均有显著影响。基于多因素分析,发现PD1(DFS:HR:3.202;P = 0.011,OS:HR:2.671;P = 0.027)和TC-PD-L1(DFS:HR:0.174;P = 0.006,OS:HR:0.189;P = 0.009)是独立的预后标志物。在第二部分中,根据PD1和PD-L1的表达状态定义了评分系统。评分较高的患者预计DFS和OS更长。在多因素分析中,PD1/TC-PD-L1评分系统(DFS:P = 0.001,OS:P = 0.003)显示出更好的预后效果。有趣的是,在该评分的最高水平,没有患者出现复发或癌症导致的死亡。
总体而言,本研究提示TC-PD-L1蛋白具有不良预后行为,并引入PD-1/TC-PD-L1评分系统作为舌癌和喉癌HNSCC患者OS和DFS预测中的强大预后标志物。